Drug Profile
BAY 1082439
Alternative Names: BAY1082439Latest Information Update: 28 May 2020
Price :
$50
*
At a glance
- Originator Bayer
- Class Antineoplastics; Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors; Phosphatidylinositol 3 kinase beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bone metastases; Solid tumours
Most Recent Events
- 28 May 2020 No recent reports of development identified for preclinical development in Bone metastases in Germany
- 28 Nov 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Taiwan (PO)
- 28 Nov 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)